A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here’s What It Means for Grail Investors.
Multi-cancer early detection (MCED) test company Grail (GRAL 1.59%) is one of the most fascinating mid-cap healthcare stocks…